Advertisement
ALGN vs IDXX
Which Stock Would AI Choose? Align Technology (ALGN) vs. IDEXX Laboratories (IDXX) Stock Comparison
Key Takeaways
- Align Technology (ALGN) reported record Q2 2026 revenue of $1.06 billion, supported by 8.2% growth in clear aligner shipments, while IDEXX Laboratories (IDXX) delivered strong Q1 results with 14% revenue growth and awaits its Q2 earnings release on August 4.
- ALGN shares have traded in the $164–$175 range in recent weeks following its earnings release, reflecting a recovery from earlier volatility within a 52-week band of $122 to $200.
- IDXX shares have consolidated near $560–$570 levels amid a broader year-to-date decline of approximately 15%, trading below key moving averages ahead of upcoming catalysts.
- ALGN operates in the dental technology sector with exposure to consumer discretionary spending on orthodontics, whereas IDXX focuses on veterinary diagnostics with more recurring revenue streams from animal health labs and software.
- Both companies maintain premium valuations typical of healthcare innovators, with ALGN emphasizing AI-driven platform enhancements and IDXX highlighting consistent organic growth in companion animal diagnostics.
- Market sentiment for ALGN has shown short-term lift from recent results and share repurchase commitments, while IDXX sentiment remains tempered by valuation concerns and pre-earnings positioning.
Introduction
This comparison examines Align Technology (ALGN) and IDEXX Laboratories (IDXX), two healthcare-focused companies with distinct end markets but shared exposure to innovation-driven growth. ALGN serves the dental alignment and digital dentistry space, while IDXX leads in veterinary diagnostics and related software solutions. The analysis is relevant for investors and traders evaluating relative performance within the broader healthcare sector, particularly those monitoring earnings momentum, sector rotation, and valuation differentials in the current market environment.
ALGN Overview and Recent Performance
Align Technology develops and manufactures the Invisalign system of clear aligners along with digital scanners and treatment planning software for orthodontics. In recent market activity, the company posted record second-quarter 2026 revenue of $1.06 billion, up 4.3% year-over-year, fueled by strong clear aligner case shipments that rose 7.4%. Systems and services revenue declined amid softer capital equipment demand. The stock has fluctuated within a narrow band following the July 29 earnings release, with shares closing at $169.16 on July 31. Recent weeks have featured announcements of new AI-powered workflow tools on the Align Digital Platform and an increased 2026 share repurchase authorization of $400–500 million, contributing to a modestly positive sentiment shift after earlier volatility.
IDXX Overview and Recent Performance
IDEXX Laboratories provides diagnostic products, laboratory services, and software primarily for the companion animal veterinary market, with additional offerings in livestock and poultry health. In recent market activity, the company reported robust first-quarter 2026 results featuring 14% revenue growth and 17% EPS growth, prompting an upward revision to full-year guidance. Shares have traded in a consolidative range near $560–$570 over the past month, remaining below the 200-day moving average amid a year-to-date decline of roughly 15%. Investor attention centers on the upcoming second-quarter earnings release scheduled for August 4, 2026, with positioning influenced by valuation considerations and clinic traffic trends in the pet care sector.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots designed to identify and execute strategies across thousands of tickers. The Trending AI Robots page highlights only those bots demonstrating the strongest alignment with prevailing market conditions, drawing from a broad library that includes varied trading styles, timeframes, performance metrics, and ticker universes. Available bots span a range of historical win rates, average returns per trade, and drawdown profiles, allowing users to review detailed statistics before engagement. This section provides an informational overview of automated trading resources for market participants seeking data-driven approaches.
Head-to-Head Comparison
Align Technology (ALGN) and IDEXX Laboratories (IDXX) differ markedly in business models and growth drivers. ALGN derives the majority of revenue from discretionary clear aligner products and digital dentistry platforms, exposing it to consumer spending patterns and orthodontic demand cycles. IDXX benefits from a higher proportion of recurring diagnostic testing and software subscriptions in the animal health sector, which tends to exhibit greater stability. Recent momentum favors ALGN following its earnings beat and AI platform updates, whereas IDXX has experienced range-bound trading ahead of its quarterly report. Risk factors include ALGN’s sensitivity to macroeconomic pressures on elective procedures and IDXX’s premium valuation amid potential shifts in veterinary clinic volumes. Sector exposure places both within healthcare but with ALGN more tied to dental supplies and IDXX to animal health diagnostics, resulting in differentiated market sentiment and relative performance profiles.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, trend stability, and near-term catalysts, Tickeron’s AI models indicate a modestly higher probability of favoring Align Technology (ALGN) in the current environment due to its post-earnings momentum and platform enhancements. IDXX positioning remains constructive pending its August 4 results, with potential for sentiment shifts depending on execution. This assessment reflects probabilistic evaluation of available data rather than a definitive ranking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a StrongBuy and IDXX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 1 FA rating(s) are green whileIDXX’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 1 green, 4 red.
- IDXX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while IDXX’s TA Score has 7 bullish TA indicator(s).
- ALGN’s TA Score: 4 bullish, 5 bearish.
- IDXX’s TA Score: 7 bullish, 2 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а -0.47% price change this week, while IDXX (@Medical Specialties) price change was -2.43% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +6.30%. For the same industry, the average monthly price growth was +10.48%, and the average quarterly price growth was +7.11%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.31%. For the same industry, the average monthly price growth was +8.66%, and the average quarterly price growth was +24.82%.
Reported Earning Dates
ALGN is expected to report earnings on Oct 28, 2026.
IDXX is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+6.30% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+1.31% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ALGN | IDXX | ALGN / IDXX | |
| Capitalization | 12.4B | 45B | 28% |
| EBITDA | 877M | 1.56B | 56% |
| Gain YTD | 11.441 | -15.661 | -73% |
| P/E Ratio | 30.21 | 40.10 | 75% |
| Revenue | 4.1B | 4.45B | 92% |
| Total Cash | 1.06B | 201M | 527% |
| Total Debt | 116M | 1.11B | 10% |
ALGN | IDXX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 16 | |
PRICE GROWTH RATING 1..100 | 52 | 52 | |
P/E GROWTH RATING 1..100 | 26 | 80 | |
SEASONALITY SCORE 1..100 | 50 | 8 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (62) in the Medical Specialties industry is in the same range as IDXX (80). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IDXX (100). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for ALGN (69). This means that IDXX’s stock grew somewhat faster than ALGN’s over the last 12 months.
IDXX's Price Growth Rating (52) in the Medical Specialties industry is in the same range as ALGN (52). This means that IDXX’s stock grew similarly to ALGN’s over the last 12 months.
ALGN's P/E Growth Rating (26) in the Medical Specialties industry is somewhat better than the same rating for IDXX (80). This means that ALGN’s stock grew somewhat faster than IDXX’s over the last 12 months.
| ALGN | IDXX | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 59% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 53% |
| Advances ODDS (%) | 9 days ago 70% | 10 days ago 59% |
| Declines ODDS (%) | 14 days ago 74% | 2 days ago 70% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 51% |
Advertisement
ALGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALGN has been loosely correlated with NVST. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ALGN jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To ALGN | 1D Price Change % | ||
|---|---|---|---|---|
| ALGN | 100% | +0.61% | ||
| NVST - ALGN | 57% Loosely correlated | +0.67% | ||
| LUNG - ALGN | 52% Loosely correlated | +1.33% | ||
| XRAY - ALGN | 52% Loosely correlated | -1.72% | ||
| ICUI - ALGN | 51% Loosely correlated | -1.50% | ||
| ILMN - ALGN | 48% Loosely correlated | +0.04% | ||
More | ||||
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | -2.74% | ||
| ALGN - IDXX | 50% Loosely correlated | +0.61% | ||
| SYK - IDXX | 48% Loosely correlated | -0.27% | ||
| BLCO - IDXX | 45% Loosely correlated | -0.65% | ||
| SNN - IDXX | 44% Loosely correlated | -0.57% | ||
| STE - IDXX | 40% Loosely correlated | -0.68% | ||
More | ||||